Opus Genetics Inc. (IRD) Reports FY25 Earnings
**BREAKING: Opus Genetics Inc. Reports Q4 2025 Results**
Breaking market news, earnings coverage, and in-depth interviews with industry leaders.
**BREAKING: Opus Genetics Inc. Reports Q4 2025 Results**
Apyx Medical narrows Q4 loss to $0.06 per share as revenue surges 34.8% year-over-year to $19.2 million, with...
**Cullinan Therapeutics Inc Reports Q4 2025 Results**
**BREAKING: Prelude Therapeutics Reports Wider-Than-Expected Q4 Loss**
Prelude Therapeutics reports Q4 loss of $1.29/share, 616.7% wider than expected, despite revenue jumping to $12.1M from $6.5M...
Opus Genetics posts $0.80 Q4 loss as revenue surges 230% year-over-year to $14.2M on collaboration activity.
**SuRo Capital Corp Reports Wider-Than-Expected Q4 Loss**
Priority Technology Holdings posted Q4 adjusted EPS of $0.27, up 621% year-over-year, with revenue climbing 8.8% to $247.1...
Dyne Therapeutics narrows Q4 loss to $0.73/share vs $0.76 estimate; shares jump 19% as clinical-stage biotech shows sequential...
Septerna reports Q4 loss of $0.24/share, wider than expected, as revenue climbs to $24.1M from minimal levels earlier...
BETA Technologies reported a Q4 loss of $1.71/share vs expected $0.47 loss, but guided 2026 revenue to $130M-$135M...
Yalla Group reports Q4 adjusted EPS of $0.21 on flat sequential revenue of $83.9M, maintaining profitability but showing...